ANTEOTECH LTD — Board/Management Information 2016

Nov 13, 2016

==> picture [315 x 91] intentionally omitted <==

Chairman Not To Seek Re-election at AGM

14 November 2016

Anteo Diagnostics Limited (ASX: ADO) announces that Chairman Mark Bouris will not seek reelection to the board at today’s Annual General Meeting and therefore Mr Bouris resigns from the Board immediately prior to the commencement of the Annual General Meeting today.

“Anteo has executed significant changes this last 12 months that will stand it in good stead for the future. The recent appointment of key people including a Group Chief Executive Officer (Dr Jef Vangenechten), Chief Operating Officer – Australia (Tamara Mills) and a Group Chief Financial Officer (Peter Harding-Smith), as well as the acquisition of DIAsource, are evidence of the company’s momentum and potential.” Mr Bouris said.

“My professional commitments with Yellow Brick Road Group Holdings (ASX:YBR) and TZ Limited (ASX:TZL) have broadened in recent weeks, and relinquishing my role with Anteo Diagnostics allows me invest more time into these companies.”

About Anteo Group – Anteo Diagnostics Limited (ADO:ASX) & Subsidiaries

Anteo Group is a global nanochemistry technology and medical supply group, developing, commercialising, manufacturing and distributing products for the life sciences, clinical diagnostics and bioseparations markets, and creating new applications in the energy and medical devices sectors.

Through Anteo Technology, the Anteo Group owns a patented nanochemistry surface engineering technology which unites the strength and stability of covalent binding with the gentleness of passive binding through multi-point chelation. Through the use of its reagents binders, coatings or primers, Anteo provides materials and services for high-value commercial applications. Markets include protein binding and antibody coupling (e.g. point of care devices), primers for in-vivo medical devices and medical drug delivery, and coatings with commercial applications across a broad range of industry sectors, including life sciences, in vitro diagnostics, medical devices and energy.

Through its wholly owned subsidiary, DIAsource Immunoassays SA, Anteo Group manufactures and distributes a complete catalogue of ELISA and RIA products for clinical diagnostics via established distribution channels in 75 counties across the world, including antibodies and laboratory automation instrumentation.

For more information, please visit www.anteodx.com

Media Relations relating to Mark Bouris contact Lyndsey Douglas: +61 424 203935

==> picture [595 x 139] intentionally omitted <==